These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19098969)

  • 1. PSA testing and DRE, TRUS scanning with sector biopsy, improved histology, curative treatments, and active surveillance for prostate cancer: a success story for men's health.
    Smart R
    N Z Med J; 2008 Dec; 121(1287):57-68. PubMed ID: 19098969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer.
    Smart R
    N Z Med J; 1999 Dec; 112(1101):465-9. PubMed ID: 10678211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
    Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
    Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
    BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the diagnosis and management of prostate cancer.
    LaSpina M; Haas GP
    Can J Urol; 2008 Aug; 15 Suppl 1():3-13; discussion 13. PubMed ID: 18700060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen best practice statement: 2009 update.
    Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
    J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and treatment of early prostate cancer].
    Zhu G; Liu M; Wan B
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):693-6, 712. PubMed ID: 16209214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is prostate cancer screening justified in the Bedouin population?
    Abdallah M; Lazarev I; Ariad S; Mermershtain W
    Onkologie; 2009 May; 32(5):260-2. PubMed ID: 19420972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local-regional prostate cancer.
    Jones MJ; Koeneman KS
    Urol Oncol; 2008; 26(5):516-21. PubMed ID: 18774466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening: the continuing controversy.
    Wilbur J
    Am Fam Physician; 2008 Dec; 78(12):1377-84. PubMed ID: 19119557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.